GPT and metabolic dysfunction-associated steatohepatitis: Additional biomarkers such as liver fat, plasma ALT, and serum Pro-C3 biomarkers have been routinely employed in NASH clinical studies; their inclusion in a NASH QSP model further enhances its utility.